Show simple item record

dc.contributor.authorMcLean, Samantha L.*
dc.contributor.authorGrayson, Ben*
dc.contributor.authorMarsh, S.*
dc.contributor.authorZarroug, S.H.O.*
dc.contributor.authorHarte, Michael K.*
dc.contributor.authorNeill, Joanna C.*
dc.date.accessioned2016-06-06T14:40:00Z
dc.date.available2016-06-06T14:40:00Z
dc.date.issued2016
dc.identifier.citationMcLean SL, Grayson B, Marsh S, Zarroug SHO, Harte MK and Neill JC (2016) Nicotinic α7 and α4β2 agonists enhance the formation and retrieval of recognition memory: potential mechanisms for cognitive performance enhancement in neurological and psychiatric disorders. Behavioural Brain Research. 302: 73-80.
dc.identifier.urihttp://hdl.handle.net/10454/8460
dc.descriptionYes
dc.description.abstractCholinergic dysfunction has been shown to be central to the pathophysiology of Alzheimer’s disease and has also been postulated to contribute to cognitive dysfunction observed in various psychiatric disorders, including schizophrenia. Deficits are found across a number of cognitive domains and in spite of several attempts to develop new therapies, these remain an unmet clinical need. In the current study we investigated the efficacy of donepezil, risperidone and selective nicotinic α7 and α4β2 receptor agonists to reverse a delay-induced deficit in recognition memory. Adult female Hooded Lister rats received drug treatments and were tested in the novel object recognition (NOR) task following a 6 h inter-trial interval (ITI). In all treatment groups, there was no preference for the left or right identical objects in the acquisition trial. Risperidone failed to enhance recognition memory in this paradigm whereas donepezil was effective such that rats discriminated between the novel and familiar object in the retention trial following a 6 h ITI. Although a narrow dose range of PNU-282987 and RJR- 2403 was tested, only one dose of each increased recognition memory, the highest dose of PNU-282987 (10 mg/kg) and the lowest dose of RJR-2403 (0.1 mg/kg), indicative of enhanced cognitive performance. Interestingly, these compounds were also efficacious when administered either before the acquisition or the retention trial of the task, suggesting an important role for nicotinic receptor subtypes in the formation and retrieval of recognition memory.
dc.description.sponsorshipThis work was conducted at the University of Bradford and was funded by b-neuro. However all our recent studies mentioned in the discussion section have been conducted at the University of Manchester (UoM), and funded by b-neuro, Autifony, Innovate UK (formerly TSB) and UoM
dc.language.isoen
dc.rights© 2016 Elsevier. Reproduced in accordance with the publisher's self-archiving policy. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectObject recognition memory
dc.subjectFemale rat
dc.subjectDelay-dependent deficits
dc.subjectα7 Nicotinic receptors
dc.subjectα4β2 Nicotinic receptor
dc.titleNicotinic α7 and α4β2 agonists enhance the formation and retrieval of recognition memory: potential mechanisms for cognitive performance enhancement in neurological and psychiatric disorders
dc.status.refereedYes
dc.date.Accepted27/08/2015
dc.date.application30/08/2015
dc.typeArticle
dc.type.versionAccepted manuscript
dc.identifier.doihttps://doi.org/10.1016/j.bbr.2015.08.037
dc.rights.licenseCC-BY-NC-ND
refterms.dateFOA2018-07-25T14:00:58Z
dc.openaccess.statusopenAccess


Item file(s)

Thumbnail
Name:
McLean_Behavioural_Brain_Resea ...
Size:
565.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record